ViaNautis Bio welcomed SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury ViaNautis Bio, the biotech developing polyNaut® for precise, non‑viral delivery of genetic medicines, announced that SCI Ventures, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the […]
Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]
The World Cup kicked off this week and so did our clients, with new appointments, important clinical trial updates and major collaborations announced! The Optimum team was proud to support and attend Weatherden’s Symposium on Women’s Health yesterday, which featured a stellar line-up of speakers to explore how smarter clinical development and regulatory strategy can […]
Collaboration will evaluate Scenic’s first-in-class PLA2G15 inhibitor program in Parkinson’s disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving lysosomal health as a therapeutic angle for Parkinson’s disease Amsterdam, The Netherlands — 11 June, 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose function‑first genomics engine has […]
